HONG KONG – U.S. regulators have given the green light to 12 biosimilars and the EU has cleared a whopping 53. China, however, has lagged behind, though industry experts are predicting the first biosimilar could clear regulatory hurdles this year.
HONG KONG – U.S. regulators have given the green light to 12 biosimilars and the EU has cleared a whopping 53. China, however, has lagged behind, though industry experts are predicting the first biosimilar could clear regulatory hurdles this year.
HONG KONG – Cellular Biomedicine Group Inc. has inked a partnership with Novartis AG to bring Kymriah (tisagenlecleucel) to market in China, putting it in a race with competing CAR T-cell therapy Yescarta (axicabtagene ciloleucel, Gilead Sciences Inc.), which is expected to soon start clinical trials in the country.
HONG KONG – Cellular Biomedicine Group Inc. has inked a partnership with Novartis AG to bring Kymriah (tisagenlecleucel) to market in China, putting it in a race with competing CAR T-cell therapy Yescarta (axicabtagene ciloleucel, Gilead Sciences Inc.), which is expected to soon start clinical trials in the country. (See BioWorld, Sept. 13, 2018.)
HONG KONG – With the U.S. approval under its belt, Verastem Inc. is looking at China as the next big market for Copiktra (duvelisib), inking an exclusive licensing deal with CSPC Pharmaceutical Group Ltd., of Shijiazhuang, China, in exchange for $15 million up front in deal for rights to develop and commercialize Copiktra for all oncology indications in China.
HONG KONG – With the U.S. approval under its belt, Verastem Inc. is looking at China as the next big market for Copiktra (duvelisib), inking an exclusive licensing deal with CSPC Pharmaceutical Group Ltd., of Shijiazhuang, China, in exchange for $15 million up front in deal for rights to develop and commercialize Copiktra for all oncology indications in China.
HONG KONG – South Korean pharmaceutical and biotech companies have been given new guidelines on how to treat research and development spending in their accounting, a move expected to remove uncertainties related to R&D's impacts on companies' return on assets and return on invested capital.
HONG KONG – South Korean pharmaceutical and biotech companies have been given new guidelines on how to treat research and development spending in their accounting, a move expected to remove uncertainties related to R&D's impacts on companies' return on assets and return on invested capital.
HONG KONG – Shanghai-based Fosun Kite Biotechnology Co. Ltd. was granted approval from China's National Medical Products Administration (NMPA) to advance its gene therapy candidate, FKC-876, to clinical trials.
